SPY326.54-3.44 -1.04%
DIA265.06-1.53 -0.57%
IXIC10,911.59-274.00 -2.45%

Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy at ASN Kidney Week

Results demonstrate a greater than 65% mean reduction in proteinuria at week 48 in C3G patients treated with pegcetacoplan Sustained improvements were seen across key clinical measures at 48 weeks There are no

· 10/09/2020 10:15
  • Results demonstrate a greater than 65% mean reduction in proteinuria at week 48 in C3G patients treated with pegcetacoplan

  • Sustained improvements were seen across key clinical measures at 48 weeks
  • There are no approved medicines for C3G, a rare disease that often leads to kidney failure